Upregulation of nuclear factor-κB (NF-κB) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus or disease outcome in cervical cancer

Diagnostic Cytopathology

Volumn 34, Issue 8, 2006, Pages 555-563

  Branca, M ^a   Giorgi, C ^a   Ciotti, M ^b   Santini, D ^c   Di Bonito, L ^d   Costa, S ^c   Benedetto, A ^b   Bonifacio, D ^d   Di Bonito, P ^a   Paba, P ^b   Accardi, L ^a   Mariani, L ^e   Ruutu, M ^f   Syrjanen S ^f   Favalli, C ^b   Syrjänen, Kari ^a,g  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d MAGGIORE HOSPITAL   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF TURKU   (Finland)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cervical cancer; CIN; CIN treatment; Nf B; Oncogenic human papillomavirus; Persistence; Prognosis; Virus clearance

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PERSISTENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; WART VIRUS;

ADOLESCENT; ADULT; AGED; ALPHAPAPILLOMAVIRUS; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NF-KAPPA B; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 33746637977     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.20514     Document Type: Article

References (41)

1. zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2002;2:342-350.
2. Syrjänen K, Syrjänen S. Papillomavirus infections in human pathology. Chichester, UK: Wiley; 2000. 615 p.
3. Aubin F, Pretet JL, Mougin C (editors). Papillomavirus Humains. Biologie et pathologie tumorale. Paris: TEC & DOC; 2003. 759 p.
4. Campo S (editor). Papillomavirus research: From natural history to vaccines and beyond. UK: Caister Academic Press; 2006. 456 p.
5. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527.
6. Cliffort GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: Pooled analysis. Lancet 2005;366:991-998.
7. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002;38:2229-2242.
8. Longatto Filho A, Utagawa ML, Shirata NK, et al. Immunocytochemical expression of p16INK4A and Ki-67 in cytologically negative and equivocal pap smears positive for oncogenic human papillomavirus. Int J Gynecol Pathol 2005;24:118-124.
9. INK4A expression is related to grade of CIN and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 2004;23:354-365.
10. Branca M, Ciotti M, Santini D, et al. Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer. Am J Clin Pathol 2004;122:902-911.
11. Chun KS, Surh YJ. Signal transduction pathways regulating cyclooxygenase-2 expression: Potential molecular targets for chemoprevention. Biochem Pharmacol 2004;68:1089-1100.
12. Shishodia S, Aggarwal BB. Nuclear factor-κB activation: A question of life and death. J Biochem Mol Biol 2002;35:28-40.
13. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniais T. Transcriptional regulation of endothelial cell adhesion molecules: NF-κB and cytokine-inducible enhancers. FASEB J 1995;9:899-909.
14. Chen F, Castranova V, Shi X. New insights into the role of nuclear factor-κB in cell growth regulation. Am J Pathol 2001;159:387-397.
15. Ruutu M, Peitsaro P, Johansson B, Syrjänen S. Transcriptional profiling of a human papillomavirus 33-positive squamous epithelial cell line which acquired a selective growth advantage after viral integration. Int J Cancer 2002;100:318-326.
16. Baeuerle PA, Baltimore D. NF-κB: Ten years after. Cell 1996;87:13-20.
17. Karin M, Ben-Nariah Y. Phosphorylation meets ubiquitination: The control of NF[kappa]B activity. Annu Rev Immunol 2000;18:621-663.
18. Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-310.
19. Fontaine V, van der Meijden E, de Graaf J, ter Schegget J, Struyk L. A functional NF-κB binding site in the human papillomavirus type 16 long control region. Virology 2000;272:40-49.
20. Spitkovsky D, Hehner SP, Hofmann TG, Moller A, Schmitz ML. The human papillomavirus oncoprotein E7 attenuates NF-κB activation by targeting the IκB kinase complex. J Biol Chem 2002;277:25576-25582.
21. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. Papillomavirus type 16 oncogenes downregulate expression of interferon- responsive genes and upregulate proliferation-associated and NF-κB-responsive genes in cervical keratinocytes. J Virol 2001;75:4283-4296.
22. Patel D, Huang SM, Baglia LA, McCance DJ. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 1999;18:5061-5072.
23. Nair A, Venkatraman M, Maliekal TT, Nair B, Karunagaran D. NF-κB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene 2003;22:50-58.
24. Branca M, Giorgi C, Santini D, et al. Aberrant expression of vascular endothelial growth factor-C (VEGF-C) is related to grade of cervical intraepithelial neoplasia (CIN) and high-risk human papillomavirus (HPV), but does not predict virus clearance after treatment of CIN or prognosis of cervical cancer. J Clin Pathol 2006;59:40-47.
25. Syrjänen KJ. Immunohistochemistry in assessment of molecular pathogenesis of cervical carcinogenesis. Eur J Gynaecol Oncol 2005;26:118-124.
26. Branca M, Costa S, Mariani L, et al. Assessment of risk factors and human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-Pathogen ISS study. Eur J Gynaecol Oncol 2004;25:689-698.
27. Costa S, Terzano P, Santini D, et al. CD44 isoform 6 (CD44v6) is a prognostic indicators of the response to neoadjuvant chemotherapy in cervical carcinoma. Gynecol Oncol 2001;80:67-73.
28. Costa S, Terzano P, Santini D, et al. Neoadjuvant chemotherapy in cervical carcinoma: Regulators of cell cycle, apoptosis and proliferation as determinants of response to therapy and disease outcome. Am J Clin Pathol 2001;116:729-737.
29. Costa S, Simone PD, Venturoli S, et al. Factors predicting human papillomavirus (HPV) clearance in cervical intraepithelial neoplasia (CIN) lesions treated by conization. Gynecol Oncol 2003;90:358-365.
30. Svehlikova V, Wang S, Jakubikova J, Williamson G, Mithen R, Bao Y. Interactions between sulforaphane and apigenin in the induction of UGT1A1 and GSTA in CaCo-2 cells. Carcinogenesis 2004;25:1629-1637.
31. Bauer HM, Greer CE, Manos M. Determination of genital human papillomavirus infection using consensus PCR. In: Herrington CS, McGee JOD, editors. Diagnostic molecular pathology: A practical approach. Oxford: Oxford University Press; 1992. p 132-152.
32. Karlsen F, Kalantari M, Jenkins A, et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 1996;34:2095-2100.
33. Kleter B, van Doom LJ, Scrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999;37:2508-2517.
34. Branca M, Giorgi C, Santini D, et al. Aberrant expression of a novel inhibitor of apoptosis (Survivin) is related to grade of cervical intraepithelial neoplasia (CIN), but does not predict virus clearance after cone or prognosis in cervical cancer. Am J Clin Pathol 2005;124:113-121.
35. Branca M, Giorgi C, Ciotti M, et al. Down-regulation of nucleoside diphosphate (NDP) kinase nm23-H1 expression is unrelated to high-risk human papillomavirus (HPV) but associated with progression of CIN and unfavourable prognosis of cervical cancer. J Clin Pathol 2006, in press.
36. Vancurova I, Wu R, Miskolci V, Sun S. Increased p50/p50 NF-κB activation in human papillomavirus type 6- or type 11-induced laryngeal papilloma tissue. J Virol 2002;76:1533-1536.
37. Du J, Chen GG, Vlantis AC, Xu H, Tsang RK, van Hasselt AC. The nuclear localization of NFκB and p53 is positively correlated with HPV16 E7 level in laryngeal squamous cell carcinoma. J Histochem Cytochem 2003;51:533-539.
38. Shier MK, Neely EB, Ward MG, et al. Correlation of TGFβ1 overexpression with down-regulation of proliferation-inducing molecules in HPV-11 transformed human tissue xenografts. Anticancer Res 1999;19:4969-4976.
39. Vikhanskaya F, Falugi C, Valente P, Russo P. Human papillomavirus type 16 E6-enhanced susceptibility to apoptosis induced by TNF in A2780 human ovarian cancer cell line. Int J Cancer 2002;97:732-739.
40. Havard L, Delvenne P, Frare P, Boniver J, Giannini SL. Differential production of cytokines and activation of NF-κB in HPV-transformed keratinocytes. Virology 2002;298:271-285.
41. Prusty BK, Husain SA, Das BC. Constitutive activation of nuclear factor κB: Preferential homodimerization of p50 subunits in cervical carcinoma. Front Biosci 2005;10:1510-1519.